These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35128882)

  • 1. [Prospects and reflections on the research and development of next-generation malaria vaccines].
    Xiao B; Huang ZH; Jiang LB
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):555-556. PubMed ID: 35128882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development and application of the world's first malaria subunit vaccine RTS, S/AS01].
    Xu WY
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):557-559. PubMed ID: 35128883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The world's first malaria vaccine: Hope and challenge].
    Zhang YL; Pan WQ
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):560-562. PubMed ID: 35128884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Potential challenges for large-scale uses of RTS, S/AS01 vaccine in malaria-endemic areas].
    Feng GQ
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):553-554. PubMed ID: 35128881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Advanced Development Pathway of the RTS,S/AS01 Vaccine.
    von Seidlein L
    Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
    Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
    PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
    Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
    PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Field evaluation and future applications of the world's first malaria vaccine].
    Gao Q
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):551-552. PubMed ID: 35128880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
    Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
    Vandoolaeghe P; Schuerman L
    Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
    RTS,S Clinical Trials Partnership
    PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel malaria vaccines.
    Laurens MB
    Hum Vaccin Immunother; 2021 Nov; 17(11):4549-4552. PubMed ID: 34347570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status.
    Gyaase S; Asante KP; Adeniji E; Boahen O; Cairns M; Owusu-Agyei S
    BMC Public Health; 2021 Jan; 21(1):240. PubMed ID: 33509156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
    Mahmoudi S; Keshavarz H
    Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
    Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
    PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
    Agnandji ST; Fernandes JF; Bache EB; Ramharter M
    Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of high human genetic diversity in Africa on immunogenicity and efficacy of RTS,S/AS01 vaccine.
    Tukwasibwe S; Mboowa G; Sserwadda I; Nankabirwa JI; Arinaitwe E; Ssewanyana I; Taremwa Y; Tumusiime G; Kamya MR; Jagannathan P; Nakimuli A
    Immunogenetics; 2023 Jun; 75(3):207-214. PubMed ID: 37084013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RTS,S/AS01 Malaria Vaccine - The Next Step for a Developing Country.
    Zehra A; Syed B; Masood F
    J Prev Med Hyg; 2022 Mar; 63(1):E130-E131. PubMed ID: 35647385
    [No Abstract]   [Full Text] [Related]  

  • 20. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
    Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M
    Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.